Review
Nature Reviews Cancer 6, 789-802 (October 2006) | doi:10.1038/nrc1977
Topoisomerase I inhibitors: camptothecins and beyond
Yves Pommier1 About the author
Abstract
Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme. It is the only known target of the alkaloid camptothecin, from which the potent anticancer agents irinotecan and topotecan are derived. As camptothecins bind at the interface of the TOP1–DNA complex, they represent a paradigm for interfacial inhibitors that reversibly trap macromolecular complexes. Several camptothecin and non-camptothecin derivatives are being developed to further increase anti-tumour activity and reduce side effects. The mechanisms and molecular determinants of tumour response to TOP1 inhibitors are reviewed, and rational combinations of TOP1 inhibitors with other drugs are considered based on current knowledge of repair and checkpoint pathways that are associated with TOP1-mediated DNA damage.
- View At a Glance
Author affiliations
-
Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892-4255, USA.
Email: pommier@nih.gov
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Research HighlightsNature Structural & Molecular Biology News and Views (01 Aug 2007)
Enzymes that push DNA aroundNature Structural Biology News and Views (01 Oct 1999)
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3BOncogene Original Article
Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell linesBritish Journal of Cancer Original Article
See all 30 matches for Research